Paradigm Shift

In Cancer Treatment

Learn More

Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.

Our technology targets the epigenetic causes of cancer which is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Our technology may also apply to hormonal cancers such as prostate, breast, ovarian cancer and perhaps other conditions like leukemia.

Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.

News & Events

October 8, 2019

Press Release

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

Salarius Targeting Key Safety and Efficacy Data Milestones in 2020

HOUSTON, Oct. 8, 2019 — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage
oncology company targeting the epigenetic causes of cancers, announced today that Memorial
Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital
(Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing
Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma. The addition of
MSKCC and Nationwide Children’s brings the total number of active clinical trial sites to eight.

September 13, 2019

Press Release

Salarius Pharmaceuticals Announces Senior Leadership Changes

Salarius Pharmaceuticals Announces Senior Leadership Changes

Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer

HOUSTON, Sept. 13, 2019 — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to the new role of Chief Business Officer and the appointment of Mark Rosenblum to the position of Executive Vice President Finance and Interim Chief Financial Officer. These changes are intended to enhance Salarius’ focus on financial operations and strategic value creation while its lead clinical programs in Ewing sarcoma and advanced solid tumors continue to advance toward potential data milestones in 2020.  Epigenetics refers to the regulatory system that affects gene expression and can cause cancer.  Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease.